Received May 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | P2443 | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
early 3rd dose; Late 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 73-year-old male patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 22-MAY-2025, the patient received the 3rd dose of Twinrix. On 09-APR-2025, the patient received the 2nd dose of Twinrix. On 09-APR-2025, not applicable after receiving Twinrix and an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd dose). On 22-MAY-2025, the patient experienced drug dose administration interval too short (Verbatim: early 3rd dose). The outcome of the drug dose administration interval too short and drug dose administration interval too long were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 22-MAY-2025 The reporter called and reported that they gave a Twinrix vaccine outside the normal interval, so they wanna now if did they need to repeat the dose. they gave the 3rd dose to soon. The vaccine administration facility was the same as primary reporter. The healthcare professional reported that the 2nd dose was a late 2nd dose which led to lengthening of vaccination schedule, and the 3rd dose was an early which led to shortening of vaccination schedule.
TWINRIX